Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,584 total articles
The Elmet Group's wholly owned subsidiary, Elmet Technologies, has been awarded a $36 million contract by the Defense Logistics Agency to supply high-performance molybdenum and tungsten alloys and precision wire used in jet engine components and aerospace applications. This award builds on a prior $2 billion DLA tungsten contract and further streng…
Skyward Group announces the expansion of its ibott subsidiary's autonomous vehicle insurance expertise into the U.S. primary insurance market, offering a comprehensive suite of innovative insurance products tailored to the evolving risks in the autonomous vehicle ecosystem. Leveraging deep industry expertise, data-driven approaches, and Skyward's b…
Autonomix Medical announced positive feedback from the FDA indicating a potential Class II 510(k) clearance pathway leveraging substantial equivalence to an already-cleared device for its standalone transvascular sensing platform. The company targets U.S. clearance in approximately 15 months, which marks a significant step toward commercializing it…
SEALSQ Corp, a US-listed company specializing in semiconductors and post-quantum cybersecurity, emphasizes the capabilities of its French subsidiary IC'Alps in designing custom, low-power, secure ASICs tailored for implantable and connected medical devices. The acquisition strengthens SEALSQ's position in the growing medical electronics market by c…
Candel Therapeutics disclosed novel data from phase 2 and phase 3 trials showing that aglatimagene besadenovec, combined with external beam radiation therapy, induces durable local and systemic immune activation in intermediate-risk localized prostate cancer. The phase 3 trial demonstrated significant reductions in risk of recurrence and metastasis…
TOMI Environmental Solutions announced that Project MEND, a nonprofit refurbishing and redistributing medical equipment, is using TOMI's SteraMist ionized hydrogen peroxide (iHP) technology to disinfect durable medical equipment such as wheelchairs, hospital beds, and mobility aids before reuse. This partnership highlights SteraMist's capability to…
Skyworks Solutions, Inc. announced receiving all necessary regulatory approvals to proceed with its previously announced merger with Qorvo, Inc. The transaction, expected to close around October 5, 2026, will combine their complementary technologies to form a leading U.S.-based global player in high-performance radio frequency, analog, and mixed-si…
Battalion Oil Corporation announced the release of its updated September 2026 investor presentation, detailing its strategic priorities, Delaware Basin asset portfolio, financial position, and outlook through 2027. The company highlighted its balance-sheet improvements, capital-efficient growth plans, and commitment to transparent investor communic…
Decoy Therapeutics, a NASDAQ-listed biotechnology company specializing in designing multi-antiviral peptides across viral families, announced that CEO Rick Pierce will present at The Small Cap Showcase in New York City. The presentation will cover corporate overview and investor meetings, highlighting their AI-driven IMP³ACT platform and lead antiv…
AIB Data Centers Inc. has signed a binding agreement with Nebius for 50 MW of critical IT capacity at its southeastern U.S. data center. The deal includes long-term customer prepayments and financing, reducing equity dilution risk, and leverages existing electrical infrastructure to deploy AI-focused data halls efficiently. This marks a significant…
Regency Centers Corporation, a leading national REIT specializing in shopping centers, will release its third quarter 2026 earnings after market close on November 5, 2026, followed by a conference call on November 6, 2026.
Foresight Autonomous Holdings Ltd. announced its decision to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE) effective January 4, 2027, while continuing to trade its American Depositary Shares (ADSs) on the Nasdaq under ticker FRSX. This move aims to reduce costs and administrative complexity associated with dual list…
Terra Innovatum Global N.V. (NASDAQ: NKLR), a developer of advanced micro-modular nuclear reactors, announced upcoming participation in three major investor conferences to discuss progress in licensing, industrialization, and commercialization of its SOLO™ micro-modular reactor. The company is advancing its Nuclear Regulatory Commission licensing p…
Candel Therapeutics presented biomarker data from its phase 3 trial of aglatimagene besadenovec showing significant and sustained immune remodeling in patients with localized intermediate- to high-risk prostate cancer over two years following treatment combined with radiation. The AI-enabled analysis showed increased lymphocyte infiltration and tum…
Ardelyx, a US-based biopharmaceutical company, received multiple honors at the 2026 PM360 Trailblazer Awards, including CEO of the Year for Mike Raab, a Gold Award for its podcast 'Gut Matters,' and a Silver Award for the IBSRELA marketing team. These awards recognize Ardelyx's growth, innovation, patient-focused initiatives, and leadership in the …
Esperion Therapeutics, wholly owned by ARCHIMED, is rolling out ENBUMYST, an intranasal bumetanide nasal spray for short-term treatment of edema in heart failure patients. This new administration route offers a non-invasive alternative to IV diuretics and aligns with upcoming CMS Ambulatory Specialty Model payment reforms starting 2027. Esperion ai…
NuCana plc announced that the European Patent Office has granted a key composition-of-matter patent for its novel anti-cancer agent NUC-7738, reinforcing its intellectual property protection across major markets. This milestone advances NuCana's long-term commercial strategy and supports ongoing Phase 1/2 clinical trials combining NUC-7738 with pem…
CTS Corporation has introduced its first Digital Temperature Sensor platform, expanding its portfolio with high-accuracy digital sensing solutions designed for industrial, medical, transportation, and electronics sectors. This new platform offers precise temperature measurement with digital communication capabilities, multiple probe styles, and sim…
AEON Biopharma announced that the FDA's Type 2b meeting provided constructive feedback on the development of ABP-450, its biosimilar to BOTOX®, indicating acceptance of previously completed comparative studies as supportive evidence and endorsing a comparative pharmacodynamic study design. The company plans to submit an IND for the pharmacodynamic …
Silexion Therapeutics has dosed the first patient in its global Phase 2/3 clinical trial evaluating SIL204, an RNAi therapeutic for KRAS-mutated locally advanced pancreatic cancer. The study combines direct intratumoral and subcutaneous delivery with standard chemotherapy to improve treatment efficacy. The trial initiated at Tel Aviv Sourasky Medic…
Trio Petroleum Corp announced that its Canadian subsidiary acquired 24 oil wells from Marlin Resources in Saskatchewan's Lloydminster region, including 4 producing and 20 shut-in heavy-oil wells. The deal incorporates production of approximately 37 barrels of oil per day with significant upside from a proposed Cummings multilateral well and workove…
Eupraxia Pharmaceuticals announced promising 52-week Phase 1b/2a RESOLVE trial results for EP-104GI, showing sustained clinical remission and histologic improvements in patients with Eosinophilic Esophagitis (EoE) after a single dose. The treatment demonstrated favorable safety with no serious adverse events, supporting potential for a once-annual …
Immutep Limited, a late-stage immunotherapy biotech firm, has received approximately A$856,669 from the Australian Federal Government's R&D tax incentive program for its 2025 fiscal year expenditures. The funding, including additional French and German tax incentives, supports the advancement of its cancer and autoimmune disease therapies, notably …
Rank One Computing Corporation (ROC) announced its ROC-003 algorithm secured the top global position for age estimation accuracy across three primary datasets in the National Institute of Standards and Technology (NIST) Face Analysis Technology Evaluation for Age Estimation and Verification (FATE AEV). This achievement solidifies ROC's transition f…
Celcuity Inc. announced that its drug REVTORPYK (gedatolisib) is now commercially available in the United States for treatment of hormone receptor-positive, HER2-negative advanced breast cancer patients without PIK3CA mutation, following progression on endocrine therapy. REVTORPYK, a first-in-class inhibitor of all class I PI3K isoforms and mTOR co…
